Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 8;13(2):415–435. doi: 10.1007/s40120-024-00582-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig. 2 — Variations from baseline in MMDs (a), MMDs with acute medications (b), and by migraine frequency (c, d), respectively. Change from baseline was calculated as: post-baseline value − baseline value, and the “most recent time point” refers to either the time frame “month 13 to month 15 during follow-up” or to “1 to 3 months after galcanezumab treatment interruption.” Based on the frequency of migraine, the population was stratified into chronic and episodic migraine subgroups at baseline. CM Chronic migraine, EM episodic migraine, MMDs monthly migraine days, n number of patients with mean change from baseline, SD standard deviation

Fig. 2 — Variations from baseline in MMDs (a), MMDs with acute medications (b), and by migraine frequency (c, d), respectively. Change from baseline was calculated as: post-baseline value − baseline value, and the “most recent time point” refers to either the time frame “month 13 to month 15 during follow-up” or to “1 to 3 months after galcanezumab treatment interruption.” Based on the frequency of migraine, the population was stratified into chronic and episodic migraine subgroups at baseline. CM Chronic migraine, EM episodic migraine, MMDs monthly migraine days, n number of patients with mean change from baseline, SD standard deviation